There is a big hope that artificial intelligence (AI) will be transformative in drug discovery and development. Progress is fast moving with many AI, machine learning and advance analytics companies regularly approaching Novartis with capabilities that may have the potential to advance research and development. At Novartis, we are developing a standard process for benchmarking that: (i) scientifically evaluates and compares innovation on real tasks important to drug development R&D, (ii) de-risks external engagement by removing the need to provide sensitive data during evaluation, (iii) and reduces internal resources required to engage external partners but also increasing the capacity to scale future collaboration.

Download the slides for this talk.Download ( PDF, 7607.07 MB)